secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2023-05-23T23:59:59+00:00
Accession:  0000917520-23-000035
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.06, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Integra LifeSciences initiates global product recall due to endotoxin issues, cuts guidance
--------------------------------------------------------------------------------

- Voluntary recall of SurgiMend, PriMatrix, Revize, TissueMend from Boston facility (March 2018 – May 2023).
- Expects $22M inventory impairment charge in Q2 ending June 30, 2023; no cash impact.
- Q2 2023 guidance revised: revenue $372M-$376M, adjusted EPS $0.55-$0.59.
- If stoppage continues through 2023, full-year revenue impact ~$60M, EPS ~$0.35.
- Boston facility products represent ~5% of consolidated revenues; manufacturing halt extended.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752023000035/0000917520-23-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752023000035/iart-20230522.htm
  HTML page:      https://secwatch.observer/filing/0000917520-23-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer